Miromatrix Medical (MIRO) Stock Price, News & Analysis

Company Overview

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

Key Stats

• Today's Range: $3.39 to $3.39
• 50-Day Range: $3.31 to $3.40
• 52-Week Range: $0.91 to $4.35
• Volume: N/A
• Average Volume: 80,095 shs
• Market Capitalization: $92.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MIRO Stock Analysis - Frequently Asked Questions

How were Miromatrix Medical's earnings last quarter?

Miromatrix Medical Inc. (NASDAQ:MIRO) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.12. The business had revenue of $0.01 million for the quarter. Miromatrix Medical had a negative trailing twelve-month return on equity of 120.49% and a negative net margin of 2,861.17%.

When did Miromatrix Medical IPO?

Miromatrix Medical (MIRO) raised $32 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 4,000,000 shares at a price of $7.00-$9.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What other stocks do shareholders of Miromatrix Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Miromatrix Medical investors own include BitNile Metaverse (BNMV), Cognition Therapeutics (CGTX), Impel Pharmaceuticals (IMPL), Nyxoah (NYXH), Aceragen (ACGN), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 5/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MIRO
• CIK: 1527096
• Web: www.miromatrix.com
• Phone: 952-942-6000
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,960,000.00
• Net Margins: -2,861.17%
• Pretax Margin: -2,861.17%
• Return on Equity: -120.49%
• Return on Assets: -90.70%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 3.46
• Quick Ratio: 3.46

Sales & Book Value

• Annual Sales: $958,029.00
• Price / Sales: 97.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: 2.71

Miscellaneous

• Outstanding Shares: 27,419,000
• Free Float: 25,993,000
• Market Cap: $92.95 million
• Optionable: Optionable
• Beta: 0.01